Is NRXS or NTLA more undervalued in 2026?

CirclFi compares Neuraxis, Inc. (NRXS) and Intellia Therapeutics, Inc. (NTLA) using 13 institutional-grade valuation models. NRXS has a Quality of Company score of 6.9/10 while NTLA scores 6.5/10.

Which is a better buy — NRXS or NTLA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NRXS and NTLA valuations compare?

NRXS at $7.29 and NTLA at $13.68 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NRXS vs NTLA Valuation Comparison 2026 — Intrinsic Value Analysis

NRXS

Biotechnology

Neuraxis, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$7.29

Last close

Models

10/13

Active

NTLA

Biotechnology

Intellia Therapeutics, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$13.68

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	NRXS Fair Value	NRXS Upside	NTLA Fair Value	NTLA Upside
Bayesian DCF	Intrinsic	$2.04	-72.0%	$4.02	-70.6%
Earnings Power Value	Intrinsic	$1.57	-80.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	—	—	$0.55	-95.5%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NRXS vs NTLA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NRXS vs NTLA — Which Stock Is More Undervalued?

NRXS scores higher with a 6.9/10 quality rating vs NTLA's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Neuraxis, Inc. (NRXS) and Intellia Therapeutics, Inc. (NTLA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NRXS currently trades at $7.29 with a QOC of 6.9/10, while NTLA trades at $13.68 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).